Charter Oak Capital Management LLC Acquires Shares of 24,003 SI-BONE, Inc. (NASDAQ:SIBN)

Charter Oak Capital Management LLC acquired a new position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 24,003 shares of the company's stock, valued at approximately $337,000. Charter Oak Capital Management LLC owned 0.06% of SI-BONE at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in shares of SI-BONE by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after buying an additional 2,100 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of SI-BONE by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after purchasing an additional 3,867 shares during the last quarter. Paradigm Capital Management Inc. NY lifted its stake in SI-BONE by 5.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company's stock worth $19,432,000 after purchasing an additional 69,831 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in SI-BONE by 8.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company's stock valued at $1,439,000 after buying an additional 7,855 shares during the period. Finally, Virtus Fund Advisers LLC bought a new position in shares of SI-BONE during the fourth quarter valued at about $40,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on SIBN shares. Truist Financial boosted their price objective on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th.

Insider Buying and Selling

In other SI-BONE news, CFO Anshul Maheshwari sold 4,937 shares of the company's stock in a transaction on Wednesday, May 7th. The shares were sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the transaction, the chief financial officer now directly owns 265,356 shares in the company, valued at approximately $4,511,052. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of SI-BONE stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the sale, the senior vice president now owns 244,878 shares in the company, valued at approximately $3,462,574.92. This trade represents a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 95,942 shares of company stock valued at $1,734,203 over the last 90 days. Insiders own 4.00% of the company's stock.

SI-BONE Stock Performance

Shares of SIBN stock traded down $0.23 on Monday, reaching $18.67. The stock had a trading volume of 42,890 shares, compared to its average volume of 382,126. The stock has a market cap of $795.62 million, a P/E ratio of -20.29 and a beta of 0.94. The company has a 50 day simple moving average of $16.10 and a 200 day simple moving average of $15.56. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $20.05.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. Equities research analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current year.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.